Endocrine Testing Market 2024 – By Size, Share, Trends And Growth Prospects 2033

The endocrine testing global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Endocrine Testing Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size – The endocrine testing market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to discovery of hormones and endocrine pathways, diagnostic test standardization, public health initiatives, and patient advocacy and empowerment.

The endocrine testing market size is expected to see strong growth in the next few years. It will grow to $3.67 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing prevalence of endocrine disorders, increased defense spending, aging population, awareness and early diagnosis, and increased awareness. Major trends in the forecast period include advancements in biomarker detection, integration of omics technologies, artificial intelligence and machine learning, quality assurance and standardization, and collaborative research and translational medicine.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Scope Of Endocrine Testing Market

The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Endocrine Testing Market Overview

Market Drivers -The rising prevalence of diabetes is expected to propel the growth of the endocrine testing market going forward. Diabetes refers to a group of diseases that result in high blood sugar (glucose) levels. The prevalence of diabetes is increasing due to factors such as unhealthy diets, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine testing, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, is used in diabetes to diagnose the condition, monitor glucose levels, and assess insulin production and sensitivity. For instance, in 2021, according to the International Diabetes Federation, a US-based umbrella organization of over 230 national diabetes associations in 170 countries, approximately 537 million adults (20-79 years) were living with diabetes in the world. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the endocrine testing market.

Market Trends – Major companies operating in the endocrine testing market are developing point-of-care testing solutions to enhance the accessibility and efficiency of diagnosing endocrine disorders. Point-of-care testing allows for quick results, which can aid in the rapid diagnosis and management of heart failure in patients presenting with symptoms such as shortness of breath and fatigue. For instance, in April 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched a point-of-care NT-proBNP test in India, specifically designed for screening diabetes patients at risk of cardiovascular diseases, such as heart failure (HF). It facilitates early detection and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions. The test facilitates early detection and intervention, allowing the clinicians to identify high-risk T2D patients and initiate timely treatment discussions, ultimately fostering improved outcomes and patient well-being.

The endocrine testing market covered in this report is segmented –

1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types

2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal & Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies

3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers , Other End-Users

Get an inside scoop of the endocrine testing market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15562&type=smp

Regional Insights – North America was the largest region in the endocrine testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies – Major companies operating in the endocrine testing market are  Thermo Fisher Scientific Inc., Abbott Laboratories, Roche Holding, Siemens Healthineers, Quest Diagnostics, Agilent Technologies Inc., PerkinElmer Inc., BioMérieux SA, Beckman Coulter Inc. , Bio-Rad Laboratories Inc., SD Biosensor Inc., Qiagen N.V., Ortho Clinical Diagnostics , Kronus Inc., Randox Laboratories Ltd., Fujirebio Diagnostics Inc., Inova Diagnostics Inc., Sekisui Diagnostics LLC, Mercodia AB, ZEUS Scientific Inc., IBL International, Monobind Inc., Agilus Diagnostics, Tosoh Bioscience Inc., DiaSorin S.p.A.

Table of Contents
1. Executive Summary
2. Endocrine Testing Market Characteristics
3. Endocrine Testing Market Trends And Strategies
4. Endocrine Testing Market – Macro Economic Scenario
5. Global Endocrine Testing Market Size and Growth
…………………………..
32. Global Endocrine Testing Market Competitive Benchmarking
33. Global Endocrine Testing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Endocrine Testing Market
35. Endocrine Testing Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model